Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Leerink Partners
Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and ...
Hosted on MSN1d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
I-Mab to Participate in Leerink Partners Global Healthcare Conference
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in ...
FiercePharma2d
Leerink group goes beyond conventional metrics to evaluate cost-effectiveness of key therapies
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
Leerink Partnrs Estimates Genmab A/S Q3 Earnings
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Hosted on MSN6d
Leerink Partners Upgrades Genmab A (GMAB)
Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. Analyst Price Forecast Suggests 558.90% Upside As of ...